Biocompatibility and Functionality of a Tissue-Engineered Living Corneal Stroma Transplanted in the Feline Eye

Marie Boulze Pankert,1,2 Benjamin Goyer,3 Fatma Zaguia,1 Myriam Bareille,1 Marie-Claude Perron,1 Xinling Liu,1,4 J. Douglas Cameron,5 Stéphanie Proulx,3,6 and Isabelle Brunette1,4

1Maisononneuve-Rosemont Hospital Research Center, Montreal, Québec, Canada
2Département d’ophthalmologie, Université d’Aix-Marseille, Marseille, France
3Centre de recherche du CHU de Québec, Axe médecine régéneratrice, Hôpital St-Sacrement, CUG-Research, and Centre de recherche en organogenèse expérimentale de l’Université Laval/LOEX, Québec City, Québec, Canada
4Department of Ophthalmology, University of Montreal, Montreal, Québec, Canada
5Ophthalmology and Visual Neurosciences and Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, Minnesota, United States
6Département d’ophthalmologie et d’oto-rhino-laryngologie - chirurgie maxillo-faciale, Faculté de médecine, Université Laval, Québec City, Québec, Canada

Cite this article as:

Corneal tissue shortage has become a major concern worldwide, which has motivated the search for alternative solutions to eye bank human eyes for corneal transplantation. Minimally invasive lamellar transplantation and tissue engineering may offer new opportunities for the rehabilitation of diseased corneas. The aim of this study was to evaluate the biocompatibility and functionality of stromal lamellar grafts tissue-engineered (TE) in vitro and transplanted in vivo in the cornea of a feline model.

METHODS. The corneal stromas were engineered in culture from corneal stromal cells using the self-assembly approach, without the addition of exogenous material or scaffold. Eight healthy animals underwent two intrastromal grafts in one eye and the contralateral eye was used as a control. Animals were followed with slit-lamp ophthalmic examination, corneal esthesiometry and optical coherent tomography. Confocal microscopy, immunofluorescence, histology, and transmission electron microscopy (TEM) were performed at 4 months.

RESULTS. Four months after transplantation, the TE-stromal grafts were transparent, functional, and well tolerated by the eye. All grafts remained avascular, with no signs of immune rejection, despite a short course of low-dose topical steroids. Corneal sensitivity returned to preoperative level and reinnervation of the grafts was confirmed by confocal microscopy and immunofluorescence. Histology and TEM of the TE-grafts showed a lamellar stromal structure with regular collagen fibril arrangement.

CONCLUSIONS. These results open the way to an entirely new therapeutic modality. Intracorneal filling using a biocompatible, transparent, and malleable TE-stroma could be the basis for multiple types of novel therapeutic options in corneal interventional surgery.

Keywords: tissue engineering, corneal transplantation, corneal stroma, corneal substitute, reinnervation, cell culture

Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. www.iovs.org | ISSN: 1552-5786
A variety of synthetic and acellular biomaterials aimed at replacing the corneal stroma have been experimentally tested, with mitigated success. Polyvinyl alcohol hydrogel\textsuperscript{11} and expanded polytetrafluoroethylene implants,\textsuperscript{12} for instance, offer interesting optical properties and low immunogenicity, but are compromised by low cell affinity or biocompatibility. Biocompatibility is improved with polyethylene glycol-diacrylate\textsuperscript{13} or type I collagen, chitosan, and glycossaminoglycans\textsuperscript{14} implants; however, with variable degrees of transparency and tendency for biodegradation. In an attempt to improve in vivo stability, corneal stromal cells have been introduced on the surface or within various substrates, such as synthetic polymers\textsuperscript{15} and gelatin hydrogel.\textsuperscript{16} These results have highlighted the benefits of generating cytotcompatible biomaterials in order to improve biointegration of the stromal implant.

An intermediate option, consisting of a cell-free scaffold permeable to the host's corneal cells and nerves, has been proposed by Griffith's group. This stromal substitute made of cross-linked recombinant human collagen was implanted in 10 human subjects,\textsuperscript{17} which represents an advance in the field of stromal replacement.

The new concept proposed herein combines both alternatives of tissue engineering and lamellar transplantation. The stromal tissue described herein is different and complementary to that of an acellular biosynthetic implant or scaffold, as it is entirely engineered from stromal cells (keratocytes) prior to transplantation. Keratocytes can be isolated and easily expanded to form thick corneal stroma.\textsuperscript{26} This approach is now used to engineer stromal fibroblasts to secrete and assemble their own extracellular matrix without the addition of exogenous biomaterial. The stromal sheets generated are then stacked to form a thicker stromal substitute.\textsuperscript{19} This approach is now used to engineer skin transplants for the treatment of severe burns\textsuperscript{20} and lower-extremity chronic skin ulcers.\textsuperscript{21} It is also under investigation for the engineering of blood vessels\textsuperscript{22} and adipose tissue.\textsuperscript{23} The corneal stromal tissue produced with this technique opens the door to an entirely new generation of therapeutic options for the rehabilitation of a wide range of diseased corneas. The aim of this study was to evaluate the biocompatibility and functionality of this corneal stromal tissue engineered in vitro using the self-assembly technique and transplanted in vivo in the cornea of a feline model.

**Materials and Methods**

All experiments were conducted in accordance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research for the duration of all the experiments. The research protocol was approved by the Maisonneuve-Rosemont Hospital Animal Protection committee.

**Tissue Engineering of the Corneal Stroma**

**Isolation and Culture of Human and Feline Corneal Cells.** The human corneas of a 26-day-old human donor unsuitable for transplantation were obtained from our local eye bank (Banque d’Yeux du Centre Universitaire d’Ophtalmologie, Québec, QC, Canada). Keratocytes were isolated after dispase digestion and removal of the epithelium and endothelium. They were cultured in fibroblast culture medium consisting of DMEM supplemented with 10% fetal calf serum (HyClone, Logan, UT, USA), 25 µg/mL gentamicin sulphate (Schering, Pointe Claire, QC, Canada), and 100 IU/mL penicillin G (Sigma, Oakville, ON, Canada).\textsuperscript{24,26} Feline keratocytes were isolated (n = 1 pair of eyes) and cultured using the same protocol as for human cells.

**Tissue Engineering of Human and Feline Stromas Using the Self-Assembly Approach.** Corneal fibroblasts were seeded at a density of 100 cells/mm\textsuperscript{2} and cultured in fibroblast growth medium supplemented with 50 µg/mL ascorbic acid (Sigma) for 28 (feline cells) or 35 (human cells) days. Fibroblasts secreted their own extracellular matrix and generated thick sheets, six of which were stacked to produce a thick corneal stroma.\textsuperscript{26}

**In Vitro Assessment of Stromal Compatibility With Neurite Outgrowth.** Compatibility with reinnervation was assessed in vitro. Sensory neurons (given by François Berthod) were extracted from the dorsal root ganglion (DRG) of mice embryos (E12.5, CD-1 mice; Charles River Laboratories, Lasalle, QC, Canada).\textsuperscript{27} washed, and trypsinized. We seeded 2000 DRG/mm\textsuperscript{2} on the tissue-engineered corneal stromas and cultured in growth medium containing 10 ng/mL nerve growth factor (Feldan, Quebec, QC, Canada) for 14 and 21 days.\textsuperscript{28} Tissues were then processed for immunofluorescent labeling. None of the tissues seeded with DRG were transplanted in vivo.

**Population**

Eight healthy domestic felines aged between 10.3 and 19.4 months (15.4 ± 3.5 months) and weighing between 2.7 and 4.7 kg (3.7 ± 0.9 kg) were used for this study. One eye per animal was randomly assigned to transplantation of two TE-stromal grafts and the contralateral eye was used as a control. Four animals received grafts engineered from feline cells (allografts) and four animals received grafts engineered from human cells (xenografts).

**Surgical Protocol**

Surgery was performed under general anesthesia.\textsuperscript{29} Two limbal incisions 4-mm long and 300-µm deep were made poles apart in the superior nasal and inferior temporal quadrants, using a micrometric diamond knife (Meyco; Anton Meyer & Co., Ltd., Biel, Switzerland) and a 7-mm long intrastromal lamellar dissection was made toward the center of the cornea using a crescent knife (Alcon Canada, Inc., Mississauga, Canada). Two TE-stromal grafts were cut (4-mm Acupunch; Acuderm, Inc., Fort Lauderdale, FL, USA) and a graft was inserted in each intrastromal pocket, leaving a 2-mm clear zone between the graft and the limbus (Fig. 1). In the mate control eye, a similar lamellar dissection was made in the inferior temporal quadrant without tissue insertion. No sutures were applied to any of the grafts and all limbal wounds were closed (CU-1 100-nylon; Alcon Surgical, Fort Worth, TX, USA).

**Postoperative Medication**

At the end of the surgery, animals received subconjunctival injections of dexamethasone (1.2 mg in 0.3 mL), tobramycin (10 mg in 0.25 mL), and ceftazolin (55 mg in 0.25 mL). Sutures were removed on day 7. During the postoperative period, tobramycin 0.3% and dexamethasone 0.1% (Tobradex; Alcon Canada, Inc.) and diclofenac 0.1% drops (Voltaren Ophthalmic; Novatis Pharmaceuticals Corp., East Hanover, NJ, USA) were applied three times a day for the first week and tapered over 1 month. No systemic antibiotics or steroids were given. Prophylactic famciclovir (Famvir 125 mg/day per OS; Novatis Pharmaceutical Corp.) was given during the entire study period.

**Standard Follow-up**

Animals were examined before surgery, daily from postoperative days 1 to 4, on days 7, 8, 10, 15, 18, 22, 25, and 30, and once a
week for the last 3 months. Each ophthalmic examination included slit-lamp photography (Haag-Streit, Bern, Switzerland); intraocular pressure measurement (Perkins handheld Tonometer Mk2; Haag-Streit, Edinburgh, UK); and central and midperipheral corneal pachymetry (ultrasound pachymeter SP 3000; Tomey, Nagoya, Japan). Two independent trained observers made all corneal examinations. Eyes were checked for graft clarity, signs of infection, inflammation, rejection, and neovascularization. Graft transparency was quantified according to a subjective 0 to +4 scale.\(^{30}\) (4+: clear graft allowing full visualization of iris details; 3+: slight opacity with iris/lens details easily visible; 2+: mild opacity, iris/lens still visible; 1+: moderate opacity with no iris/lens details; and 0: opaque cornea). The presence of cells and flare in the anterior chamber was used to quantify inflammation according to a 0 to +4 scale.\(^ {31}\) Corneal neovascularization was described in terms of superficial or deep, length, number of clock hours of limbal involvement, and flow rate (0: ghost vessel; +1: low flow; +2: high flow).

**Corneal Sensitivity.** Corneal sensitivity was measured using an esthesiometer (Cochet-Bonnet, 12/100 mm nylon thread; Luneau, Chartres, France).\(^ {52,33}\) On an awake and quiet animal, the nylon monofilament was applied perpendicularly to the corneal surface and shorted by 0.5-cm steps, from 6.0 cm (soft) to 0.5 cm (rigid). The longest filament length generating a blink reflex in more than half of five applications was recorded as the corneal sensitivity threshold. Measurements were performed in the anterior temporal, central, and superior nasal zones of all corneas.

**Optical Coherence Tomography (OCT).** Real-time OCT (Thorlabs, Inc., Newton, NJ, USA) was used to obtain in vivo noncontact, two-dimensional, cross-sectional images with resolution in the order of 4.4 \( \mu \text{m} \). Corneal and graft thicknesses and graft depth were measured using ImageJ software (http://image.nih.gov/ij/; provided in the public domain by the National Institutes of Health [NIH], Bethesda, MD, USA).\(^ {34}\) The central, superior nasal, and inferior temporal zones of both corneas were studied. We performed OCT on days 3, 15, 30, 44, and months 2, 3, and 4 after surgery. Six cross-sectional images (four horizontal and two vertical) were acquired for each zone of interest.

**Confocal Microscopy.** Confocal microscopy (Rostock cornea module of Heidelberg Retina Tomograph II: RCM/HRT II; Heidelberg Engineering GmbH, Heidelberg, Germany) was performed on all eyes. Images (400 \( \times \) 400 \( \mu \text{m} \); 384 \( \times \) 384 pixels) were obtained with a transversal optical resolution of 2 \( \mu \text{m} \), an axial optical resolution of 4 \( \mu \text{m} \) and an acquisition time of 0.024 seconds. Semiautomated sequences of 30 images with incremental steps of 2 \( \mu \text{m} \) were obtained from epithelium to endothelium, in the central, superior nasal, and inferior temporal zones of all corneas.

Nerve fiber analyses were focused on the subbasal nerve plexus (just anterior to Bowman’s layer; \( n = 6 \) consecutive images), the subepithelial nerve plexus (just posterior to Bowman’s layer; \( n = 2 \) consecutive images) and the TE-stromal grafts (\( n = 3 \) consecutive images for each anterior, middle, and posterior third). Each nerve was only counted once. All analyses were repeated at corresponding depth in the control eye. The nerve tracing and analysis software (NeuronJ; Biomedical Imaging Group, Lausanne, Switzerland and Rotterdam, The Netherlands) was used in combination with the ImageJ software.\(^ {54,56}\) A single observer masked for animal’s identity, type of graft and clinical results made the analyses. Five previously validated parameters were studied: \(^ {33,57–59}\)

1. Nerve count, representing the total number of nerves observed within a 400 \( \times \) 400 \( \mu \text{m} \) frame (expressed in number/mm\(^2\));
2. Density (\( \mu \text{m/mm}^2 \)), defined as the cumulative length of all nerves visible within a frame;
3. Length (\( \mu \text{m} \)), defined as the average length of nerves within a frame;
4. Width (\( \mu \text{m} \)), defined as the average width of nerves within a frame; and
5. Branching, which was described as present or absent.

**Histology, Electron Microscopy, and Indirect Immunofluorescence.** Histology, electron microscopy, and indirect immunofluorescence analyses were performed on the preoperative TE-stromas, on the grafts, as well as on the operated and unoperated native controls. One quarter of each cornea was fixed in 10% neutral buffered formalin and paraffin embedded.
FIGURE 2. Histology and immunofluorescent staining of the TE-stromas. (A, B) Histology cross-sections (Masson trichrome staining). (A) Tissue-engineered stroma in culture prior to transplantation showing fibroblasts imbedded between six sheets of extracellular matrix (Masson trichrome stains collagen in blue and cells in purple). \( N = 9 \) TE-stromas, \( n = 4 \) photographed sections per stroma. A representative photograph was chosen for the figure. (B) Tissue-engineered stromal graft 4 months after implantation in the feline cornea. (\( N = 8 \) grafted corneas + 8 control corneas, \( n = 3 \) full thickness corneal sections per grafted or control cornea. A representative picture was chosen for the figure. (C, D) Pretest in culture:
immunofluorescent staining of a subgroup of TE-stromas seeded with DRGs. None of the TE-stromas seeded with DRGs were transplanted in vivo. (C) En face view showing neurite outgrowth from the DRG cell bodies (NF68, green). Representative picture of four TE-stromas. (D) Cross-sectional view showing detection of the 68K Da neurofilament (NF68; green) across the entire tissue thickness. We visualized the TE-stroma using an antibody directed specifically toward human type IV collagen (Coll IV, red). Cell nuclei were counterstained with Hoechst (blue). Representative picture of three TE-stromas. (E) Immunofluorescent staining of the TE-stromal graft 4 months after transplantation (NF68; green) and type IV collagen (red). Cell nuclei were counterstained with Hoechst (blue). (F–I) Immunofluorescent staining of the TE-stromal grafts 4 months after transplantation. (F) Type I collagen (red). (G) Type V collagen (green). (H) Hoechst staining (blue). (I) Merge of (F–H) N = 8 grafted corneas. A representative region was chosen for the figure. (J) Human–HLA-ABC staining of a human TE-stroma transplanted in the feline eye 4 months after transplantation. The dotted lines delineate the grafted TE-stroma. N = 3 grafted corneas. A representative region was chosen for the figure. Scale bars: 20 μm (A); 50 μm (B–J).

In Vivo Assessment

Graft Transparency. The 16 intrastromal grafts of the TE-stroma laid at an average corneal depth of 272 ± 50 μm (182–417 μm). Once transferred to their natural environment, the grafts rapidly cleared out. The average graft transparency score improved rapidly to 3.3 ± 0.4 on the first postoperative day and 3.9 ± 0.2 on day 37, after which all grafts remained clear, allowing full visualization of the fine iris details with the same precision as for native corneas (Figs. 3A, 3B). These grafts were so clear that confirmation of their presence necessitated bright tangential illumination, as shown in Figure 3A (second row).

Intraocular Inflammation and Pressure.

There were no signs of inflammation in any of the eyes prior to surgery. The minimal intraocular inflammation observed in the anterior chamber of all eyes (grafted and controls) on day 1 entirely resolved within a few days (Figs. 3C, 3D). All corneas remained avascular (a condition essential to preserve transparency) and no signs of rejection, such as graft edema, stromal infiltration or keratic precipitates, were seen at any time in any of the grafted eyes. Beside a small and transient rise early after surgery, intraocular pressure remained unaffected by surgery (Fig. 3E).

Endothelial Cell Density and Graft Thickness.

Endothelial cell counts remained unchanged (preop grafted eyes: 2521 ± 197, postop grafted eyes: 2470 ± 139 cells/mm², P = 0.182; preop control eyes: 2490 ± 181, postop control eyes: 2495 ± 150, P = 0.928) and endothelial function unaffected, as corroborated by the rapid resorption of graft edema. The average graft thickness decreased from 44.5 ± 7.8 μm on day 3 to 31.2 ± 4.9 on day 114 (P ≤ 0.0001; Fig. 3F).

Conical Sensitivity Assessed by Esthesiometry

Postoperative recovery of corneal sensitivity is illustrated in Figure 3G. Before surgery, the average corneal sensitivity was 5.4 ± 0.5 cm in the central cornea, 2.5 ± 0.8 cm in the superior nasal midperiphery and 2.7 ± 0.8 cm in the inferior temporal midperiphery, with no differences between the two eyes (P ≤ 1.000). Surgery resulted in a significant decrease in corneal sensitivity in all midperipheral zones where the cornea was cut, whether a graft was inserted or not. Sensitivity progressively returned to normal during the study period in all the midperipheral zones (preop: 2.6 ± 0.8 cm; day 3: 0.1 ± 0.2 cm [P ≤ 0.0001]; day 114: 3.1 ± 0.6 cm [P = 0.002]). Sensitivity in the central cornea was not affected by surgery (P = 0.196). By the end of the study, all sensitivity values converged to a mean value of 6.0 ± 0.0 cm in the central cornea and 3.1 ± 0.6 cm in the midperiphery. The slight

for light microscopy. A second quarter was fixed in 2.5% glutaraldehyde and prepared for transmission electron microscopy (TEM, Hitachi H-7500; Tokyo, Japan) as previously described.30 We used TEM images (×100,000 and ×200,000) to analyze distribution, diameter, and spacing of the stromal collagen fibrils. Forty collagen adjacent fibrils were randomly selected and measured in each sample. The ImageJ software was used.34

One half of each cornea was frozen in optimal cutting temperature solution (Somagen, Edmonton, AB, Canada) for immunodetection.7 We fixed 20-μm cryosections 10 minutes at −20°C using acetone (90%; EMD Serono Canada, Inc., Mississauga, ON, Canada) for all of the immunostainings except for anti-HLA, which were fixed 10 minutes at room temperature in 16% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) then permeabilized 30 minutes in 0.2% Tween-20 (Millipore Corp., Toronto, ON, Canada). Primary antibodies consisted of a chicken anti-neurofilament 68 kDa (NF68; Millipore Corp.), a mouse anti-collagen I (Calbiochem; VWR International, Mississauga, ON, Canada); a rabbit anti-collagen IV human (Millipore Corp.); a rabbit anti-collagen V (Cedarlane; Hornby, ON, Canada); and a mouse anti-human HLA-ABC (Millipore Corp.). Goat anti-chicken conjugated with AlexaFluor 488, donkey anti-mouse conjugated with AlexaFluor 488 or 594 and goat anti-rabbit conjugated with AlexaFluor 594 or 488 (all from Invitrogen Life Technologies, Burlington, ON, Canada) were used as secondary antibodies.

Cell nuclei were counterstained with Hoechst reagent 33258. Fluorescence was observed using a confocal microscope (LSM700, Carl Zeiss Canada Ltd., Toronto, ON, Canada). One transversal 0.36-μm image, taken in the middle of the TE-stroma, was used for the observation of NF68. Images (319.49 × 319.49 μm; 2048 × 2048 pixels) were obtained with a z-stack of 0.36 μm. Only one stack, taken in the middle of the TE-stroma, was used for the observation of NF68.

Statistical Analysis

The mean ± SD was used to describe continuous variables. Statistical comparisons between groups were performed using Student’s t-test derived from a mixed model ANOVA. An unstructured covariance structure was used and the assumption of normality of the residuals was assessed. The mixed model was used to account for the correlation among multiple measures of an outcome on the same subject at different time points and/or different corneal zones.

RESULTS

In Vitro Characterization of the Engineered Stromal tissue

Figures 2A through 2J illustrate the histological progression of the TE-stromas from culture to the eye. Figure 2A shows the in vitro corneal stroma with six sheets of extracellular matrix. The mean thicknesses (±SD) of the engineered stromas in culture was 61 ± 15 μm (N = 9, n = 27; 38–100 μm). Before transplantation, compatibility with axonal outgrowth was assessed by seeding and culturing the TE-stromas with sensory DRG. The sensory neurons seeded on top of the TE-stromas yielded axonal outgrowth on the surface, as well as within the deeper layers of the TE-stromas (Figs. 2C, 2D).
FIGURE 3. Clinical outcome of the TE-intrastromal grafts. (A) Representative slit-lamp photos 4 days (column 1), 1 month (column 2), and 4 months (column 3) after transplantation of a TE-stroma in the superior nasal quadrant. Regular diffuse illumination (first row) does not allow visualization of the clear graft, which can only be seen with direct tangential illumination (second row; arrow; same graft and ×10 magnification for all six photographs). (B–G) Clinical evolution of grafted and control eyes. (B) Transparency score. (C) Anterior chamber cell score. (D) Anterior chamber flare score. (E) Intraocular pressure. (F) Graft thickness. (G) Esthesiometry. The parameters described in this figure were measured in all eyes at all indicated time points, with no missing data. The most representative photos are shown.
Histopathology 4 months after transplantation showed smooth integration of the grafts, without surrounding scar tissue, inflammatory cellular infiltration, or vascular invasion (Fig. 2B). The multilayered epithelium and the endothelial monolayer appeared undisturbed. The stromal grafts were homogeneous, with a more compact lamellar arrangement than that seen in culture. Fibroblasts were more numerous in the grafts than in the host stroma.

**Nerves, Cells, and Collagen Content Assessed by Immunofluorescence**

The presence of multiple nerve filaments within these grafts 4 months after transplantation confirmed active reinnervation by the host (Fig. 2E). These new nerves tended to grow between and parallel to the stromal lamellae of the graft. Immunostaining of the xenogenic grafts using an anti-human HLA antibody allowed to confirm that the transplanted human cells were still present in the TE-stroma 4 months after transplantation (Fig. 2J). A specific anti-human collagen IV antibody also revealed that human collagen was also present 4 months after transplantation (Fig. 2E). The expression of collagen types I and V in the TE-stroma was stronger in culture than after transplantation. By the end of the study, the expression of collagen I in the native and TE-stromas was similar, while that of collagen V was similar (Figs. 2F–I) or stronger in the grafts than in the native stroma.

**Corneal Innervation Assessed by Confocal Microscopy**

Confocal microscopy confirmed that all corneal layers were innervated after 4 months (Figs. 4A–I). The new nerves within the grafts were different from the mature nerves of the unoperated control corneas (Figs. 4J–M). They showed higher nerve counts (33 ± 14 /mm² vs. 14 ± 15 /mm², P < 0.001) and greater nerve densities (3708 ± 1237 μm/mm² vs. 2024 ± 1374 μm/mm², P = 0.002), and they tended to be shorter (20 ± 7 μm vs. 33 ± 20 μm, P = 0.064) than the mature nerves of the unoperated controls at corresponding stromal depth. Although not statistically significant, they also appeared to be wider (4 ± 2 μm vs. 3 ± 1 μm, P = 0.143) and only rarely showed branching (6% vs. 29%, P = 0.106).

The new nerves within the grafts were identical (nerve counts, density, length, width, and branching) to the new nerves found in the recipient’s stroma at the level of the incisions without a graft (P > 0.05). At the level of the subbasal and subepithelial plexus, no substantial differences were noted beside an increase in nerve density in the operated zones compared with the unoperated zones, both at the subbasal (P = 0.022) and subepithelial (P = 0.016) levels.

**Transmission Electron Microscopy**

**Corneal Stromal Fibroblasts.** Before transplantation, abundant fibroblasts were present throughout the TE-stromas (Figs. 5A, 5B). Signs of activation included an increased density in rough endoplasmic reticulum (RER) and Golgi apparatus, numerous mitochondria, chromatin margination, and prominent nucleoli (Figs. 5C, 5D).

Four months after transplantation (Figs. 5E–H), fibroblast density in the TE-stromal grafts was still greater than in the recipient’s stroma. The fibroblasts were much thinner and more elongated than in culture, their morphology being closer to that of the recipient keratocytes, which are shown in Figures 5I through 5L. While most of the features of activated fibroblasts were absent, these cells had not yet returned to a resting state.

**Extracellular Matrix and Collagen Fibris.** The TE-stroma in culture showed layers of wavy collagen fibris surrounded by abundant extracellular matrix (Figs. 5A–C, 5M). Four months after transplantation, the TE-stromal grafts showed a more compact and regular architecture (Figs. 5E–H, 5N), although still not as regular as that of the native stroma (Figs. 5I–L, 5O, 5P). Regularity of collagen fibris was greater in the anterior part of the grafts compared with the posterior part of the grafts.

The mean space between collagen fibris in the TE-stromal grafts decreased after transplantation, getting closer to that measured in nonoperated controls (P < 0.0001). Interfibrillar spacing was also larger in the host stroma surrounding the grafts (i.e., exposed to surgical manipulations) than in nonoperated controls (P < 0.0001). Mean interfibrillar distances are reported in the Table and typical examples are illustrated in Figures 5M through 5P.

The mean collagen fibril diameter in the TE-stromal grafts increased slightly after transplantation (P < 0.0001) and remained larger than that of the nonoperated controls (P < 0.001). The collagen fibris surrounding the graft were also thicker than in the nonoperated controls (P < 0.0001; Figs. 5O, 5P; Table).

**Stromal Grafts Engineered From Keratocytes of Feline Versus Human Origin.** No differences were found between the TE-grafts of feline versus human origin (transparency scores, graft thickness, corneal innervation assessed by confocal microscopy, and collagen fibris diameter and spacing as assessed by TEM; P > 0.05).

**DISCUSSION**

We present herein the first in vivo results on the transplantation of a corneal stroma entirely engineered in vitro from corneal stromal cells, without the addition of exogenous material or scaffold. The TE-corneal stromas in culture showed the lamellae structure characteristic of the native corneal stroma and were biocompatible to neurite outgrowth. Four months after transplantation in a feline animal model, the TE-stromal grafts were clinically functional and well tolerated by the eye. They were transparent, with no adverse effect noted on the normal organization and function of the recipient’s epithelial, stromal, and endothelial corneal layers, and no inflammatory reaction. There were no signs of immune rejection. Corneal sensitivity returned to preoperative level and reinnervation of the grafts was confirmed by confocal microscopy and immunofluorescence.

**Development of the Corneal Stroma**

In several aspects, this corneal stroma, tissue-engineered using the self-assembly approach and transplanted in the living eye, followed a structural development similar to that occurring in the embryonic eye.40 Proliferation of the stromal cells was followed by the deposition of layers of extracellular matrix, with loosely parallel collagen fibris. Transplantation resulted in significant thinning and compaction of the TE-stroma, with a concomitant increase in tissue transparency. Fibroblasts’ morphology evolved from a rounded to a flat shape more typical of mature keratocytes. The collagen fibris became more parallel and tightly packed, resulting in an ultrastructure increasingly homogenous and similar to that of the mature
Corneal reinnervation 4 months after surgery. (A–I) Representative confocal images illustrating the corneal nerves within the subbasal plexus (A–C), the subepithelial plexus (D–F) and the stroma (G–I), at the level of the TE-stromal graft (A, D, G), the inferior temporal quadrant of the control eye where only a surgical incision was made (B, E, H), and the superior nasal quadrant of the control eye with no incision (C, F, I). (J–M) Quantification of reinnervation, based on nerve count (J), nerve density (K), nerve length (L) and nerve width (M) at the level of the TE-stromal graft, the superior nasal quadrant of control eye with no incision and the inferior temporal quadrant of control eye with incision. The parameters described in this figure were measured in all eyes at all indicated levels, with no missing data. Each nerve was only counted once. The most representative photos are shown. Scale bar: 50 μm (same for all photographs).
native stroma. A greater regularity was observed in the anterior part of the grafts. The TE-stroma expressed collagen types I and V, two types of fibrillar collagen normally expressed in the native cornea. The fact that the extracellular matrix secreted and assembled by the corneal fibroblasts generated a stroma that did not clinically resemble scar tissue and the absence of inflammatory reaction might in part distinguish this self-engineering process from standard wound healing.

**Corneal Transparency**

Transparency of a bioengineered stroma, a sine qua non condition to light transmission and vision, and maintenance of this transparency once implanted in the living eye, is challenging. Current understanding of corneal transparency favors the role of fibril spacing, which needs to be much smaller than the light wavelength and such that fluctuations in refractive index are smaller than half the light wavelength. 41
Living Corneal Stroma Transplanted in Feline Eye

The delay in corneal transparency still needs to be improved. Progress has been made in the past decade for the production of transparent stroma. While encouraging residual haze resorbs with time, the 4-month observation period, a sign that confirms its transparency rehabilitation also has to be considered. In this study, we have gone a step further with a TE-stromal graft, allowing early and stable visualization of fine iris details during neurotrophic keratitis, resulting in chronic epithelial neuropathy and promote wound healing after eye injury. A dysfunctional corneal innervation induces a degenerative neurotrophic keratitis, resulting in chronic epithelial defects and increased risk for infection, stromal ulceration, stromal melt, and perforation. The feline model used herein was interesting because of the known similarities in innervation and sensitivity recovery between the cat and primate corneas.

In this study, the collagen fibril diameter and spacing within our TE-stromas compared favorably with literature reports. In culture, the interfibrillar spacing was closer to the native stroma, transparency still needs to be improved. Progress has been made in the past decade for the production of transparent stroma. While encouraging residual haze resorbs with time, the 4-month observation period, a sign that confirms its transparency rehabilitation also has to be considered. In this study, we have gone a step further with a TE-stromal graft, allowing early and stable visualization of fine iris details during neurotrophic keratitis, resulting in chronic epithelial neuropathy and promote wound healing after eye injury. A dysfunctional corneal innervation induces a degenerative neurotrophic keratitis, resulting in chronic epithelial defects and increased risk for infection, stromal ulceration, stromal melt, and perforation. The feline model used herein was interesting because of the known similarities in innervation and sensitivity recovery between the cat and primate corneas.

In this study, all stromal grafts were innervated 4 months after transplantation. As all TE-stromal grafts were devoid of any type of DRG or neural component at the time of transplantation, all neurons seen in the grafts in the living eye originated from the recipient. This provides additional evidence of their biointegration. The reinnervation patterns of the native and tissue-engineered stromal layers were similar, the new nerves being more numerous, shorter, thicker, and showing less branching than the mature nerves of the unoperated corneas.

The pattern and timing of reinnervation of the TE-stromal grafts were similar to those reported for native corneal grafts in human subjects. Reinnervation of native grafts is known to start 2 to 6 months after transplantation and continue to progress for several decades after transplantation. Sensitivity recovery was also similar to that reported after corneal surgery.

The main function of native keratocytes in vivo is to maintain stromal composition by synthesizing new collagen and proteoglycans, and secreting collagenases and other enzymes to degrade old matrix. Proteoglycans are known to play a major role in regulating collagen fibril size, diameter, and spatial distribution, and they are involved in the control of the swelling properties of the matrix. A variety of factors have also been shown to influence fibrillogenesis. Among them, the interaction between type V and type I collagen would be at least partially responsible for modulating collagen fibril diameter in the corneal stroma. The composition of the self-assembled extracellular matrix has been reported elsewhere.

In this study, the collagen fibril diameter and spacing within our TE-stromas compared favorably with literature reports (Table). In culture, the interfibrillar spacing was closer to native stroma than what has been reported by others using different techniques and 4 months after transplantation, it was even closer to that reported for the native human stroma. The mean collagen fibril diameter of our TE-stromas in culture was similar to that produced by the other groups. The mean collagen fibril diameter of our TE-stromas in culture was similar to that produced by the other groups. Four months after transplantation, fibrils were still somewhat larger than usually found in the native stroma.

**TABLE. Collagen Fibril Diameter and Spacing**

<table>
<thead>
<tr>
<th></th>
<th>Spacing Between Fibrils, nm</th>
<th>Fibril Diameter, nm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TE-stroma in culture (N = 9 TE-stromas; n = 40 fibrils)</td>
<td>32.0 ± 9.1</td>
<td>35.5 ± 6.0</td>
</tr>
<tr>
<td>TE-stroma at 4 months (N = 8 grafts; n = 40 fibrils)</td>
<td>25.0 ± 5.8†</td>
<td>39.5 ± 4.3†</td>
</tr>
<tr>
<td>Native tissue adjacent to graft (N = 8; n = 40)</td>
<td>22.2 ± 4.2‡</td>
<td>36.3 ± 3.5‡</td>
</tr>
<tr>
<td>Normal native control (N = 8; n = 40)</td>
<td>19.9 ± 3.9§</td>
<td>34.0 ± 3.2§</td>
</tr>
<tr>
<td>Literature</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In culture</td>
<td>56.1–60.9§,57,58</td>
<td>30–48.6§,57,58,60–63</td>
</tr>
<tr>
<td>Native stroma</td>
<td>19.6–20.9§</td>
<td>22.7–34.0§,59,64–66</td>
</tr>
</tbody>
</table>

* N indicates the number of tested tissues (TE-stromas, grafts, or controls) and n indicates the number of fibrils measured in each tissue.
† Between values in culture versus 4 months after transplantation (P < 0.0001).
‡ Between native tissue adjacent versus normal native control (P < 0.0001).
§ Between the TE-stroma at 4 months versus normal native control (spacing: P < 0.0001; diameter: P < 0.001).

**Reinnervation**

The ability of a TE-stroma to allow reinnervation is of primary importance. Corneal nerves contribute to the maintenance of a healthy ocular surface, exert a trophic influence on the corneal epithelium, and promote wound healing after eye injury. A dysfunctional corneal innervation induces a degenerative neurotrophic keratitis, resulting in chronic epithelial defects and increased risk for infection, stromal ulceration, stromal melt, and perforation. The feline model used herein was interesting because of the known similarities in innervation and sensitivity recovery between the cat and primate corneas.

In this study, all stromal grafts were innervated 4 months after transplantation. As all TE-stromal grafts were devoid of any type of DRG or neural component at the time of transplantation, all neurons seen in the grafts in the living eye originated from the recipient. This provides additional evidence of their biointegration. The reinnervation patterns of the native and tissue-engineered stromal layers were similar, the new nerves being more numerous, shorter, thicker, and showing less branching than the mature nerves of the unoperated corneas.

The pattern and timing of reinnervation of the TE-stromal grafts were similar to those reported for native corneal grafts in human subjects. Reinnervation of native grafts is known to start 2 to 6 months after transplantation and continue to progress for several decades after transplantation. Sensitivity recovery was also similar to that reported after corneal surgery.

**Immunological Tolerance**

None of our grafts showed any signs of immune reaction despite the fact that:

1. Half of these TE-stromas were produced using xenogeneic human cells;
2. These grafts were inserted in the corneal periphery, very close to the limbal vasculature; and
3. Animals received only a very short course of low dose topical steroids (much less than the 1 year and more regimen routinely administered to human subjects after corneal transplantation).

The eye benefits from immune privilege and corneal transplants are the least-rejected among all organ transplants. Furthermore, corneal rejection is typically directed against the corneal endothelium, while stromal rejection appears to be particularly rare. However, if the cellular content becomes a concern, the TE-stromal grafts could be decellularized prior
to transplantation (for instance by three freeze-thaw cycles).\textsuperscript{93} Another alternative would be to engineer stromal grafts from autologous cells, which would definitely eliminate the risk of immune rejection.

**Translational Potential, Limitations, and Further Work**

We have demonstrated the biocompatibility and functionality of lamellar TE-stromal grafts 4 months after intrastromal transplantation in the living feline eye. Quantitative characterization of the optical and mechanical properties of these grafts and implanted corneas will be needed next. Optical assessment could involve spectral transmittance,\textsuperscript{84} absorbance, and scattering measures, while biomechanical assessment should include tensile strength measurements.\textsuperscript{14} Performance of these TE-stromal grafts will then be tested for the rehabilitation of diseased corneas. Lamellar replacement of scarred corneal layers or the filling of a pathological corneal thinning are two examples of potential clinical applications. Intracorneal filling using a biocompatible, transparent, and malleable TE-stroma is presently not a therapeutic modality clinically available. This concept could be the basis for multiple types of applications in corneal interventional surgery, including compensation for a wide range of pathological corneal thinning, such as those encountered in Terrien marginal degeneration or after infectious keratitis or trauma. Intrastromal filling in these cases may allow to avoid more invasive and higher risk interventions, such as a patch graft or a full thickness corneal transplantation. Only minimal re-expansion of the stromal volume may sometimes be necessary to rehabilitate these eyes. These TE-stromas were not designed for full thickness stromal replacement and their implantation necessitates residual stromal support. Although these multilayered TE-stromas could hold a suture, no sutures need to be applied to the grafts with the intrastromal lamellar transplantation technique, thus eliminating related tissue compression, scarring, and astigmatism. Furthermore, the multilayer concept described herein may allow the thickness of the graft to adapt to individual clinical needs. There are no specific technical barriers for the transfer of these concepts to the clinic. The self-assembly approach described herein for the engineering of stromal substitutes is currently successfully used to generate other tissues (skin) for human subjects and the surgical insertion of an intrastromal lamellar graft constructs no challenge for the corneal surgeon. Other applications of TE-stromas (that would require additional investigation) may also include their use as carrier for the in vivo transplantation of a tissue-engineered corneal endothelium.\textsuperscript{6-8,30}

**Acknowledgments**

The authors thank Catherine Benoit-Normandin, François Berthod, Steve Breault, Sébastien Cadau, Santiago Costantino, André Deveault, José Ferreira, Karolyin Forget, Ellen Freeman, Lucie Germain, Angele Halley, Nour Haydari, Antoine Labbé, Jean Meunier, Olivier Rochette-Drouin, Kanwarpal Singh, and François Vidal for their technical and/or intellectual support. We also thank Élodie Samson for statistical analyses.

Supported by the Académie Nationale de Médecine, Paris, France; the Canadian Institutes for Health Research, Ottawa, Ontario, Canada; the Natural Sciences and Engineering Research Council of Canada, Ottawa, Ontario, Canada; the FRQS Vision Health Research Network, Québec, Canada; and the ThéCell FRQS Network, Québec, Canada; the Charles-Albert Poissant Research chair in Corneal Transplantation, University of Montreal, Québec, Canada (IB); and an unrestricted grant by Research to Prevent Blindness to the Department of Ophthalmology and Visual Neurosciences of the School of Medicine of the University of Minnesota (JDC). The authors alone are responsible for the content and writing of the paper.

Additional information can be obtained on request.

Disclosure: M. Boulze Pankert, None; B. Goyer, None; F. Zagui, None; M. Bareille, None; M.-C. Perron, None; X. Liu, None; J.D. Cameron, None; S. Proulx, None; I. Brunette, None

**References**


56. Lake J, Zanolo K, Gaudreault M, et al. Expression of the alpha5 integrin gene in corneal epithelial cells cultured on tissue-